I may not take every opportunity but I never and I mean never go against anything Randy says I went out of the long of unh at 3:26 and I hadn’t reentered until short yesterday so thanks for the update we’re both saying the same thing

I didn’t think you went long either that’s what I was saying in any event I took your short yesterday and much success thank you

HGRAF is in a solid uptrend so can’t make a case to short it, just yet, nor would I chase it long so extended, either. However, a sell signal/objective short entry would come on a solid break below this uptrend line as the negative divergences continue to build.

Not only is that not true but it is the opposite of what I said. In that last post where my final “official” target was slightly gapped above, I went so far to state: “However, as per the dotted arrow on the previous charts, now that UNH has entered that huge May 13th gap, there is a decent chance the gap will be backfilled, potentially providing for about a 48% profit on this trade, if so. As such, for those holding out for additional gains, consider raising stops at this time to protect profits.”

Additionally, I replied to your comment about Buffett in the comment section below that post (which I included a link to in this post above, for easy reference, BTW) further stating/clarifying: “The case to stick with UNH was made in the post above, but I would put very high odds on a reaction off that 379/gap backfill target, if hit.”

I never went long UNH again, nor do I believe I posted any updates until shorting it today, as it has hit my max. potential target from that last long trade and that very same 379/gap backfill. Here’s the link to that post for reference: https://rightsideofthechart.com/unh-united-health-final-price-target-hit-9-9-25/

Glad to provide an updated chart with commentary & levels (below) on NVDA but short of their own earnings report in 3 weeks, the biggest thing to watch for is what the big tech co’s (GOOGL, MSFT, META, etc..) report regarding future cap-ex spending that will/might, or might not, continue to benefit NVDA.